Related Experiment Video
Updated: Jul 22, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Molecular Imaging in Recurrent Prostate Cancer Presented as a Mixed Small Neuroendocrine Tumor/Acinar Adenocarcinoma
Akram Al-Ibraheem1,2, Dhuha Ali Al-Adhami1, Ahmed Saad Abdlkadir1
1Department of Nuclear Medicine, King Hussein Cancer Center, Queen Rania Street, Al Jubeiha, Amman, 11941 Jordan.
Abstract:
Molecular imaging is an important tool for evaluating patients with prostate cancer, including those with hybrid histopathology. Although rare, mixed small neuroendocrine tumor/acinar adenocarcinoma exhibit aggressive behavior that necessitates optimal therapy. Molecular imaging has been implemented previously to assess radioligand therapy eligibility in such cases. Interestingly, the uptake of radiotracers targeting prostate-specific membrane antigen (PSMA) and somatostatin receptor may be reduced and can potentially lead to false negative readings in certain tumor types with hybrid features. Therefore, physicians should be aware of different kinds of disparities when assessing these tumor types with the aforementioned modalities.
Insights
Molecular imaging aids prostate cancer evaluation, but hybrid tumors may show reduced radiotracer uptake. Physicians must recognize potential disparities in PSMA and somatostatin receptor imaging for accurate diagnosis and treatment.
Area of Science:
- Oncology
- Radiology
- Nuclear Medicine
Background:
- Molecular imaging is crucial for prostate cancer patient management.
- Mixed small neuroendocrine tumor/acinar adenocarcinoma is a rare but aggressive prostate cancer subtype.
- Current molecular imaging techniques assess eligibility for radioligand therapy.
Purpose of the Study:
- To highlight potential disparities in molecular imaging for rare prostate cancer subtypes.
- To inform physicians about reduced radiotracer uptake in mixed tumors.
- To ensure accurate assessment for targeted therapies.
Main Methods:
- Review of molecular imaging principles in prostate cancer.
- Analysis of radiotracer uptake patterns for prostate-specific membrane antigen (PSMA) and somatostatin receptors.
- Consideration of hybrid tumor histopathology.
Main Results:
- Reduced uptake of PSMA-targeting and somatostatin receptor-targeting radiotracers can occur in mixed neuroendocrine tumor/acinar adenocarcinoma.
- This reduction may lead to false-negative imaging results.
- Physicians need to be aware of these potential imaging disparities.
Conclusions:
- Molecular imaging interpretation requires careful consideration in rare prostate cancer variants.
- Awareness of reduced tracer uptake is essential for avoiding misdiagnosis.
- Optimizing diagnostic and therapeutic strategies for aggressive prostate cancer subtypes is critical.
